Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia

Anticancer Research

Volumn 31, Issue 7, 2011, Pages 2483-2488

  Kunami, Naoko ^a   Yotsumoto, Fusanori ^a   Ishitsuka, Kenji ^a   Fukami, Tatsuya ^a   Odawara, Takashi ^b   Manabe, Sadao ^b   Ishikawa, Toyokazu ^b   Tamura, Kazuo ^a   Kuroki, Masahide ^a   Miyamoto, Shingo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b Osaka University   (Japan)

Author keywords

CRM197; Doxorubicin; HB EGF; T ALL

Indexed keywords

DIPHTHERIA TOXOID CRM197; DOXORUBICIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; LIGAND; VASCULOTROPIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BACTERIAL PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; DIPHTHERIA TOXIN; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; GROWTH INHIBITORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; JURKAT CELLS; LIGANDS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 79961195639     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Pui CH, Robison LL and Look AT: Acute lymphoblastic leukaemia. Lancet 371: 1030-1043, 2008.
2. Pui CH, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC, Rubnitz JE, Razzouk BI, Howard SC, Hudson MM, Cheng C, Kun LE, Raimondi SC, Behm FG, Downing JR, Relling MV and Evans WE: Total Therapy Study XIIIB at St Jude Children's Research Hospital: Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 104: 2690-2696, 2004. (Pubitemid 39434949)
3. Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, Cohen HJ, Sallan SE and Asselin BL: Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 21: 3616-3622, 2003. (Pubitemid 46594054)
4. Grabher C, von Boehmer H and Look AT: Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 6: 347-359, 2006.
5. Aifantis I, Raetz E and Buonamici S: Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 8: 380-390, 2008.
6. Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, Tanaka Y, Yagi H, Sonoda K, Kai M, Kanoh H, Nakano H and Mekada E: Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 64: 5720-5727, 2004. (Pubitemid 39095570)
7. Yotsumoto F, Yagi H, Suzuki SO, Oki E, Tsujioka H, Hachisuga T, Sonoda K, Kawarabayashi T, Mekada E and Miyamoto S: Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun 365: 555-561, 2008. (Pubitemid 350181687)
8. Yotsumoto F, Oki E, Tokunaga E, Maehara Y, Kuroki M and Miyamoto S: HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer. Int J Cancer 127: 2707-2717, 2010.
9. Sanui A, Yotsumoto F, Tsujioka H, Fukami T, Horiuchi S, Shirota K, Yoshizato T, Kawarabayashi T, Kuroki M and Miyamoto S: HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer. Anticancer Res 30: 3143-3149, 2010.
10. Higashiyama S, Abraham JA, Miller J, Fiddes JC and Klagsbrun M: A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 251: 936-939, 1991. (Pubitemid 21926188)
11. Izumi Y, Hirata M, Hasuwa H, Iwamoto R, Umata T, Miyado K, Tamai Y, Kurisaki T, Sehara-Fujisawa A, Ohno S and Mekada E: A metalloprotease- disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J 17: 7260-7272, 1998.
12. Mitamura T, Higashiyama S, Taniguchi N, Klagsbrun M and Mekada E: Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem 270: 1015-1019, 1995.
13. Buzzi S, Rubboli D, Buzzi G, Buzzi AM, Morisi C and Pironi F: CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer Immunol Immunother 53: 1041-1048, 2004. (Pubitemid 39371748)
14. Yagi H, Yotsumoto F, Sonoda K, Kuroki M, Mekada E and Miyamoto S: Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer. Int J Cancer 124: 1429-1439, 2009.
15. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, Nowill AE, Leslie NR, Cardoso AA and Barata JT: PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 118: 3762-3774, 2008.
16. Zhao W: Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways. Leukemia 24: 13-21, 2010.
17. Chiarini F, Grimaldi C, Ricci F, Tazzari PL, Evangelisti C, Ognibene A, Battistelli M, Falcieri E, Melchionda F, Pession A, Pagliaro P, McCubrey JA and Martelli AM: Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 70: 8097-8107, 2010.
18. Demarest RM, Dahmane N and Capobianco AJ: Notch is oncogenic dominant in T-cell acute lymphoblastic leukemia. Blood 117: 2901-2909, 2011.
19. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, Caparros E, Buteau J, Brown K, Perkins SL, Bhagat G, Agarwal AM, Basso G, Castillo M, Nagase S, Cordon-Cardo C, Parsons R, Zúñiga-Pflücker JC, Dominguez M and Ferrando AA: Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 13: 1203-1210, 2007. (Pubitemid 47530629)
20. Dail M, Li Q, McDaniel A, Wong J, Akagi K, Huang B, Kang HC, Kogan SC, Shokat K, Wolff L, Braun BS and Shannon K: Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci USA 107: 5106-5111, 2010.
21. Johnston JB, Navaratnam S, Pitz MW, Maniate JM, Wiechec E, Baust H, Gingerich J, Skliris GP, Murphy LC and Los M: Targeting the EGFR pathway for cancer therapy. Curr Med Chem 13: 3483-3492, 2006. (Pubitemid 44873742)
22. Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L, Cognetti F, Tafuri A and Milella M: Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat 10: 81-100, 2007. (Pubitemid 47031052)
23. Hui RC, Gomes AR, Constantinidou D, Costa JR, Karadedou CT, Fernandez de Mattos S, Wymann MP, Brosens JJ, Schulze A and Lam EW: The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression. Mol Cell Biol 28: 5886-5898, 2008.
24. Batista A, Barata JT, Raderschall E, Sallan SE, Carlesso N, Nadler LM and Cardoso AA: Targeting of active mTOR inhibits primary leukemia T-cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol 39(4): 457-472, 2011.
25. McCarthy SA, Samuels ML, Pritchard CA, Abraham JA and McMahon M: Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes. Genes Dev 9: 1953-1964, 1995.
26. Wang F, Liu R, Lee SW, Sloss CM, Couget J and Cusack JC: Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene 26: 2006-2016, 2007.
27. Yasugi T, Sugie A, Umetsu D and Tabata T: Coordinated sequential action of EGFR and Notch signaling pathways regulates proneural wave progression in the Drosophila optic lobe. Development 137: 3193-3203, 2010.
28. Dong Y, Li A, Wang J, Weber JD and Michel LS: Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res 70: 5465-5474, 2010.